US · NCNA · BIOTECHNOLOGY
NuCana plc (NCNA) intrinsic value and stock valuation
$0.75as of 2026-11-21 · Mkt cap 8.14M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
NuCana plc DCF and intrinsic value
InvestorsCraft values NCNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NCNA’s statements →
NuCana plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-20.11M | -$-22.81M | -$-32.78M | -$-43.7M | -$-45.34M |
| Net income | -$-29.35M | -$-19M | -$-27.63M | -$-32.02M | -$-40.53M |
| EPSd | -$-7.93M | -$-3.2M | -$-5.24M | -$-6.13M | -$-9.74M |
| Operating cash flow | -$-7.47M | -$-19.12M | -$-26.44M | -$-23.16M | -$-23.82M |
| Capital expenditure | -$-190K | -$-290K | -$-480K | -$-520K | -$-1.06M |
| Free cash flow | -$-7.66M | -$-19.41M | -$-26.92M | -$-23.68M | -$-24.89M |
| Total assets | $29.8M | $14.8M | $27.8M | $58.3M | $77.5M |
| Total debt | $680K | $190K | $400K | $640K | $370K |
| Net debt | -$-23.57M | -$-6.56M | -$-16.83M | -$-41.27M | -$-59.89M |
| Total equity | $24.3M | $5.95M | $14.9M | $38.5M | $65.6M |
| Cash and short-term investments | $24.3M | $6.75M | $17.2M | $41.9M | $60.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $12.7M | $18M | $25.1M | $36.4M | $36.8M |
| Selling, general and administrative expenses | $8.1M | $4.99M | $6.06M | $7.29M | $8.53M |
| Other expenses | -$-720K | -$-100K | $1.66M | -$-4.59M | $2.54M |
| Operating expenses | $20.1M | $22.9M | $31.1M | $43.7M | $45.4M |
| Cost and expenses | $20.1M | $22.9M | $31.1M | $39.1M | $47.9M |
| Interest income | $390K | $360K | $750K | $670K | $100K |
| Interest expense | $0.00 | $0.00 | $1.1M | $0.00 | $0.00 |
| Depreciation and amortization | $270K | $520K | $570K | $730K | $940K |
| Ebitda | -$-20.56M | -$-22.48M | -$-31.78M | -$-52.15M | -$-41.88M |
| Operating income | -$-20.11M | -$-22.81M | -$-32.78M | -$-43.7M | -$-45.34M |
| Total other income/expenses, net | -$-10.41M | $360K | $750K | $5.24M | -$-2.46M |
| Income before tax | -$-30.52M | -$-22.45M | -$-32.03M | -$-38.45M | -$-47.8M |
| Income tax expense | -$-1.17M | -$-3.45M | -$-4.4M | -$-6.43M | -$-7.27M |
| Net income | -$-29.35M | -$-19M | -$-27.63M | -$-32.02M | -$-40.53M |
| Weighted average shares outstanding | $3.7M | $5.94M | $5.27M | $5.17M | $4.16M |
| Weighted average diluted shares outstanding | $3.7M | $5.94M | $5.27M | $5.22M | $4.16M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.3M | $6.75M | $17.2M | $41.9M | $60.3M |
| Net receivables | $2.51M | $4.64M | $5.83M | $50K | $8.2M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-10K |
| Total current assets | $26.9M | $12.3M | $25M | $54.9M | $71.6M |
| Property, plant and equipment, net | $890K | $200K | $520K | $870K | $850K |
| Goodwill and intangible assets | $2.96M | $2.2M | $2.13M | $2.37M | $2.41M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $2.97M | $2.51M | $2.79M | $3.33M | $5.86M |
| Total assets | $29.8M | $14.8M | $27.8M | $58.3M | $77.5M |
| Accounts payable | $520K | $2.71M | $3.38M | $4.8M | $1.83M |
| Short-term debt | $40K | $70K | $210K | $490K | $410K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $4.79M | $8.67M | $12.7M | $19.3M | $11.7M |
| Long-term debt | $660K | $120K | $190K | $400K | $160K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $710K | $150K | $250K | $440K | $210K |
| Capital lease obligations | $680K | $190K | $400K | $640K | $370K |
| Total liabilities | $5.51M | $8.82M | $12.9M | $19.8M | $11.9M |
| Common stock | $14.3M | $5.68M | $2.11M | $2.1M | $2.09M |
| Retained earnings | -$-252.33M | -$-224.29M | -$-207.71M | -$-180.57M | -$-149.73M |
| Accumulated other comprehensive income (loss) | $87.1M | $78.4M | $79.2M | $75.9M | $72.1M |
| Total equity | $24.3M | $5.95M | $14.9M | $38.5M | $65.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $680K | $190K | $400K | $640K | $370K |
| Net debt | -$-23.57M | -$-6.56M | -$-16.83M | -$-41.27M | -$-59.89M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-29.35M | -$-19M | -$-27.63M | -$-32.02M | -$-40.53M |
| Depreciation and amortization | $270K | $520K | $570K | $730K | $940K |
| Stock-based compensation | $10M | $1.65M | $3.86M | $4.89M | $6.66M |
| Change in working capital | -$-3.67M | -$-2.18M | -$-1.28M | $3.72M | $4.09M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.18M | -$-670K | -$-1.43M | $2.97M | -$-430K |
| Net cash provided by operating activities | -$-7.47M | -$-19.12M | -$-26.44M | -$-23.16M | -$-23.82M |
| Investments in property, plant and equipment | -$-190K | -$0.00 | -$0.00 | -$-520K | -$-60K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $160K | $80K | $2.89M | $120K | -$-3.56M |
| Common stock issued | $26.4M | $8.73M | $250K | $70K | $200K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $25M | $8.18M | -$-50K | -$-160K | -$-100K |
| Net change in cash | $17.5M | -$-10.48M | -$-24.69M | -$-18.35M | -$-27.09M |
| Cash at end of period | $24.3M | $6.75M | $17.2M | $41.9M | $60.3M |
| Operating cash flow | -$-7.47M | -$-19.12M | -$-26.44M | -$-23.16M | -$-23.82M |
| Capital expenditure | -$-190K | -$-290K | -$-480K | -$-520K | -$-1.06M |
| Free cash flow | -$-7.66M | -$-19.41M | -$-26.92M | -$-23.68M | -$-24.89M |
Line items
Line items
Line items
About NuCana plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
- CEO
- Hugh Stephen Griffith
- Employees
- 11
- Beta
- 2.24
Explore
Frequently asked questions
What is the intrinsic value of NuCana plc (NCNA)?
InvestorsCraft does not currently publish an intrinsic value for NCNA. How the IC value is calculated.
Is NCNA undervalued?
InvestorsCraft does not publish an undervaluation signal for NCNA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.